Industry News

• OncoGenex reports financial results for fourth quarter and fiscal year 2009  Revenue for the fourth quarter and full year of 2009 was $25.5 million, consisting of partial recognition of the non-refundable up-front payments received from Teva in December 2009.
  OncoGenex Pharmaceuticals, Inc. March 08, 2010  
• Lilly to acquire European rights to Pfizer Animal Health assets  Elanco, the animal health division of Eli Lilly and Company, announced that Lilly has signed an agreement to acquire the European rights to a portfolio of certain Pfizer Animal Health products.
  Eli Lilly and Company March 08, 2010  
• NxStage announces new FREEDOM data  NxStage Medical announced the latest interim results from its ongoing FREEDOM study, which show the significant improvement of overall sleep quality and marked improvement in Restless Legs Syndrome (RLS) experienced by patients after four months of daily home hemodialysis therapy.
  NxStage Medical, Inc. March 08, 2010  
• FDA approves NerPharMa to manufacture Cell Therapeutics' drug Pixantrone  Cell Therapeutics announced that the FDA has completed its inspection of the facility in Nerviano, Italy, which manufactures the CTI's drug pixantrone and has found the site in compliance and acceptable for continued manufacturing of the drug product.
  Cell Therapeutics, Inc. March 08, 2010  
• Agilent Technologies' executive vice president and CFO Adrian Dillon to leave company  Agilent Technologies announced that Adrian T. Dillon will resign his position as executive vice president, finance and administration, and CFO, effective April 1. Dillon will become chief financial and administration officer at Skype, based in Luxembourg.
  Agilent Technologies Inc. March 05, 2010  
• Scientists find new form of prion disease that damages brain arteries   NIH scientists investigating how prion diseases destroy the brain have observed a new form of the disease in mice that does not cause the sponge-like brain deterioration typically seen in prion diseases. Instead, it resembles a form of human Alzheimer's disease.
  National Institutes of Health March 05, 2010  
• Johnson & Johnson Consumer Companies unveils CYTOMIMIC(TM) Technology  Building on decades of research into how the body's electrical field affects skin regeneration, scientists at Johnson & Johnson Consumer Companies have discovered how to harness the power of bioelectricity to help improve skin rejuvenation.
  Johnson & Johnson March 05, 2010  
• Afexa Life Sciences announces change in year-end  Afexa Life Sciences announced that it has changed its financial year-end from September 30 to March 31 to better synchronize its financial reporting and business planning with its natural business cycle and those of its key customers and suppliers.
  Afexa Life Sciences March 05, 2010  
• ADVANCE-2 study results demonstrate investigational anticoagulant apixaban was superior  Apixaban, an oral anticoagulant being developed by Bristol-Myers Squibb and Pfizer, was statistically superior to 40 mg once daily enoxaparin in reducing the incidence of venous thromboembolism in patients undergoing elective total knee replacement surgery.
  Pfizer Inc. March 04, 2010  
• FDA approves name change for heartburn drug Kapidex  The U.S. Food and Drug Administration has approved a name change for the heartburn drug Kapidex (dexlansoprazole) to avoid confusion with two other medications – Casodex and Kadian.
  FDA March 04, 2010  

   (next 10 articles)